Â鶹´«Ã½

John Heymach, M.D., Ph.D.

John Heymach, M.D., Ph.D.

favorite_border

University of Texas MD Anderson Cancer Center

Chair of Thoracic/Head and Neck Medical Oncology

Expertise: ThoracicHead And Neck CancerLung Cancer

Primary Appointment


Chair, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX


Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston


David Bruton, Jr Chair in Cancer Research, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX


Dual/Joint/Adjunct Appointment


Professor, Department of Cancer Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

No Research/Citations

AACR: HER2 targeted therapy shows promise in previously treated lung cancers

• Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer
28-Apr-2025 05:10:47 AM EDT

Dual immunotherapy plus chemotherapy benefits specific subset of patients with lung cancer

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes were more likely to benefit from adding the immunotherapy tremelimumab to a combination of durvalumab plus chemotherapy to overcome treatment resistance typically seen in this patient population.
09-Oct-2024 09:00:24 AM EDT

Biomarker-directed combination effective in immunotherapy-resistant lung cancer

A specific combination of targeted therapy and immunotherapy may better help patients with non-small cell lung cancer (NSCLC) overcome inherent immune resistance and reinvigorate anti-tumor activity, according to a new study led by a researcher from The University of Texas MD Anderson Cancer Center.
12-Feb-2024 05:00:24 PM EST

Lung cancer outcomes significantly improved with immunotherapy-based treatment given before and after surgery

A regimen of pre-surgical immunotherapy and chemotherapy followed by post-surgical immunotherapy significantly improved event-free survival (EFS) and pathologic complete response (pCR) rates compared to chemotherapy alone for patients with operable non-small cell lung cancer (NSCLC), according to results of a Phase III trial reported by researchers at The University of Texas MD Anderson Cancer Center.
20-Oct-2023 06:00:25 PM EDT

Lung cancer study finds new target for treatment resistance after EGFR inhibitors

Researchers at The University of Texas MD Anderson Cancer Center have identified CD70 as being highly expressed on drug-resistant cancer cells in EGFR-mutant non-small cell lung cancer (NSCLC), highlighting a novel therapeutic target that could be used to eliminate resistant cells remaining after treatment with commonly used EGFR tyrosine kinase inhibitors (TKIs). The study published today in Cancer Cell.
10-Feb-2023 05:00:17 PM EST

Poziotinib is active in EGFR exon 20 mutant non-small cell lung cancer with efficacy highly dependent on insertion location

A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
08-Jul-2022 03:25:49 PM EDT

Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response

Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
29-May-2020 10:30:58 AM EDT

No Quotes

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.09043